Solara's Cuddalore facility successfully completes EU GMP Inspection

Solara Active Pharma Sciences Ltd (Solara) (NSE: SOLARA; BSE: 541540), a leading Active Pharmaceutical Ingredient / CRAMS company, today announced the successful completion EU-GMP Inspection, carried out jointly by the "State Institute for Drug Control (SUKL), Ministry of Health of the Czech Republic" and "National Authority of Medicines and Health Products (INFARMED), Portugal" from 07th to 09th February 2023, at the multi-product manufacturing facility at Cuddalore.

At the end of the inspection, it is concluded that the Quality Systems followed at our Cuddalore site is Compliant to the EU GMP Standards.

This Cuddalore facility has also successfully completed the inspection carried out by the World Health Organization (WHO) between January 23 - 26, 2023.

Jitesh Devendra, Managing Director, commented, We are happy with the successful outcome of two consecutive regulatory inspections, EU-GMP and WHO-GMP inspections at our Cuddalore facility. The result of these inspections demonstrates our commitment to regulatory excellence at our global manufacturing sites. We stay committed to high degree of compliance across Solara's manufacturing network.

The Cuddalore multi-product API manufacturing facility was established in the year 1991 and is equipped with appropriate infrastructure to include several independent production blocks and related packaging sections. This site is inspected by various Regulatory Authorities including US FDA, MHRA, EDQM, WHO, PMDA, TGA, KFDA, and COFEPRIS.

Shares of Solara Active Pharma Sciences Limited was last trading in BSE at Rs. 385.20 as compared to the previous close of Rs. 389.20. The total number of shares traded during the day was 3975 in over 804 trades.

The stock hit an intraday high of Rs. 392.10 and intraday low of 382.85. The net turnover during the day was Rs. 1539490.00.

Source : Equity Bulls

Keywords

SolaraActivePharmaSciences INE624Z01016 JointInspection SUKL Czech INFARMED Portugal Cuddalore